Serum soluble toll-like receptor 2: a novel biomarker for systemic lupus erythematosus disease activity and lupus-related cardiovascular dysfunction

International Journal of Rheumatic Diseases

Volumn 19, Issue 7, 2016, Pages 685-692

  Houssen, Maha E ^a   El Mahdy, Rasha H ^b   Shahin, Dina A ^b  

^a Damanhour University   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

lupus related cardiovascular risk factors; systemic lupus erythematosus; TLR2 signaling (sTLR2)

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; SOLUBLE TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; URIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LIPID ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 85027940096     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12452     Document Type: Article

References (31)

1. Mok C, Lau C (2003) Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56, 481–90.
2. Ryan M (2009) Pathophysiology of hypertension in systemic lupus erythematosus. Am J Physiol 296, 256–67.
3. Svnungsson E, Usrstad K, Heimburger M et al. (2001) Risk factors for cardiovascular disease in systemic lupus eythematosus. Circulation 104, 1887–93.
4. Richez C, Blanco P, Rifkin I, Moreau J, Schaeverbeke T (2011) Role of toll like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint Bone Spine 78, 124–30.
5. Huang Q, Pope R (2010) Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis. J Leukoc Biol 88, 253–62.
6. Schnar M, Barton GM, Holt AC, Akira KT, Medzhitov R (2001) Toll like receptors control activation of adaptive immune responses. Nat Immunol 2, 947–50.
7. Ueland T, Espvik T, Kjekshus J et al. (2006) Mannose binding lectin and soluble toll like receptor 2 in heart failure following acute myocardial infarction. J Card Fail 12, 659–63.
8. LeBouder E, Rey-Nores J, Rushmere N et al. (2003) Soluble forms of Toll- like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 171, 6680–9.
9. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40, 17–25.
10. Bombardier C, Gladman DD, Urowitz MB et al. (1992) The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35, 630–40.
11. Henry WL, Demariar A, Ramiak G et al. (1980) Report of the American Society of Echocardiography: nomenclature and standards in two-dimensional echocardiography. Circulation 62, 212–7.
12. Lang RM, Bierig M, Devereux RB, et al. (2006) Recommendations for chamber quantification. Eur J Echocardiogr 7 (2), 79–108.
13. Zile MR, Brutsaertd L (2002) New concepts in diastolic dysfunction and diastolic heart failure: part I & part II. Circulation 105, 1387–93, 1503–8.
14. Wahlefeld AW (1947) Triglyceride determination after enzymatic hydrolysis. In Bergemeyer HU (ed.) Methods of Enzymatic Analysis, 2nd English edn, pp. 1831. Velarg Cemie Weinheim and Academic Press Inc., London.
15. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20(4), 470–5.
16. Assmann G, Schriewer H, Schmitz G, Hagele EO (1983) Quantification of high density lipoprotein cholesterol by precipitation with phosphotungistic acid/MgCL2. Clin Chem 29, 2026–30.
17. Friedwald WT, Levy R, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 18, 499–502.
18. Mohsen T, Abdolreza V, Khakzad M, Majid M, Mojtaba S (2012) Decreased levels of soluble Toll-like Receptor2 in patients with asthma. Rep Biochem Mol Biol 1, 1–7.
19. Barham D, Trinder P (1972) An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst 97, 142–5.
20. Henry RJ (2002) Clinical Chemistry, Principles and Techniques, 2nd edn, pp. 525. Harper and Row, Henry C. Lea.
21. Takagi M (2011) Toll-like receptor A potent driving force behind rheumatoid arthritis. J Clin Exp Hematop 51, 2.
22. Urbonaviciute V, Starke C, Graef D et al. (2011) Involvement of toll like- receptor 2 in pristine- induced lupus. Ann Rheum Dis 70 (Suppl. 2), A1–94.
23. Raby A, Le Bouder E, Colmont C et al. (2009) Soluble TLR2 reduces inflammation without comprising bacterial clearance by disrupting TLR2 triggering. J Immunol 183, 506–17.
24. Krishnan J, Selvaarajoo K, Tsuciya M, Lee G, Choi S (2007) Toll like receptor signal transduction. Exp Mol Med 39, 421–38.
25. Kleijn D, Pasterkam G (2003) Toll-like receptors in cardiovascular diseases. Cardiovasc Res 60, 58–67.
26. Ha T, Liu L, Kelley J, Kao R, Williams D, Li C (2011) Toll like receptors: New players in myocardial ischemia/reperfusion Injury. Antioxid Redox Signal 15 (7), 1875–92.
27. Boyd J, Mathur S, Wang Y, Bateman R, Walley K (2006) Toll-like receptor stimulation in cardiomyocytes decreases contractility and initiates an NF-κB dependent inflammatory response. Cardiovasc Res 72, 384–93.
28. Selejan S, Poss J, Walter F et al. (2011) Ischaemia-induced up –regulation of Toll –like receptor 2 in circulating monocytes in cardiogenic shock. Eur Heart J 33 (9), 1085–94.
29. Kalia S, Dutz JP (2007) New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 20, 160–74.
30. Winder A, Lenane C, Cheetz T et al. (2009) Differential effects of cytokines and corticosteroids on toll-like receptor2 expression and activity in human airway epithelia. Respir Res 10, 96–9.
31. Lin H, Xiao H, Chen G et al. (2011) HMG-COA reductase inhibitor simvastatin suppresses Toll like receptor -2 ligand induced activation of nuclear factor kappa b by preventing Rho activation in mononocytes from rheumatoid arthritis patients. Rheumatol Int 31 (11), 1451–8.